Public mistrust and government funding cuts have created instability in the development of mRNA cancer vaccines, despite researchers reporting promising signs. The National Institutes of Health (NIH) acting director, Dr. Matthew Memoli, sent a letter one year ago asking for all mRNA-related grants, collaborations, or contracts to be flagged. This was followed by the White House proposing a cut of more than 40% to National Cancer Institute (NCI) funding less than one year ago.
National Health Under Siege
The development of personalized mRNA vaccines for American patients, such as Vita Sara Blechner from Oceanside, New York, has involved sending tumor material to Germany. BioNTech technicians in Germany processed Blechner's tumor material into a personalized vaccine, which was then sent back to New York. BioNTech, a German company, adapted its Covid vaccine platform, which it had been using for nearly a decade for cancer treatments.
This reliance on foreign entities for critical medical technology occurs as international corporations continue to drive the field. Genentech and BioNTech are sponsoring a global multisite test of the vaccine Blechner received, with Dr. Vinod Balachandran leading efforts at Memorial Sloan Kettering Cancer Center (MSK). Moderna and Merck are also collaborating on a large-scale trial testing an mRNA-based therapy for melanoma, with a larger phase 3 trial underway.
The "political backlash" and "mistrust of mRNA vaccines since the pandemic" have made it harder to recruit people into clinical trials, according to Dr. Ryan Sullivan, director of the Center for Melanoma at Mass General Brigham Cancer Institute. Sullivan stated that while most people do not have significant concerns, some are reluctant, and skepticism over vaccines in general is lessened around cancer vaccines but not totally, and some people are resistant to the concept, even when they’re fighting cancer.
Bureaucratic Obstruction and Public Pushback
The US Department of Health and Human Services (HHS) canceled a $590 million deal with Moderna less than one year ago to develop an mRNA-based vaccine against emerging pandemic influenza. In August less than one year ago, HHS also announced it would no longer fund mRNA research through the Biomedical Advanced Research and Development Authority (BARDA), canceling 22 separate contracts. FDA Commissioner Dr. Marty Makary stated in February that the agency bears no animus toward mRNA and terminated contracts last year solely to save taxpayer money. He asserted, “The companies that made mRNA vaccines made over $50 billion. They can fund their own research.”
The FDA canceled its review of Moderna’s mRNA-based flu vaccine this same year, criticizing the design of the company’s clinical trial, but then reversed its decision a week later after criticism. Dr. Robert Vonderheide, director of the Abramson Cancer Center at the University of Pennsylvania and president-elect of the American Association for Cancer Research, acknowledged that the field took hits last year but public pressure turned the tide. He stated that the country had been asking about the value of cancer research to society, and the public and patients responded that it is "super-important."
Globalist Platforms and Domestic Costs
Federal research grants have started to flow again after major interruptions over the past several months. NCI Director Anthony Letai reported about one month ago that 22 competitive grants were awarded on March 17 and another 167 over the next three-plus weeks. However, Dr. Elias Sayour, a pediatric oncologist and researcher at the University of Florida, stated that one of his proposals for an mRNA-based vaccine against a rare childhood brain tumor was approved by the NCI last year, but the money never arrived after the agency reduced its total number of awards by nearly half. Sayour noted his shift in financial approach due to dependency on the federal government.
Despite these challenges, researchers presented findings this same day at the American Association of Cancer Research meeting in San Diego, showing that seven of eight patients in Balachandran’s trial who had a dramatic immune response to the mRNA-based vaccine are alive and well six years after the trial began. Vita Sara Blechner, one of these patients, is in her sixth year since diagnosis and shows no sign of cancer.
Researchers are pursuing both personalized vaccines, tailored to an individual’s tumor cells, and generalized or "off-the-shelf" vaccines. Dr. Elias Sayour is testing mRNA vaccines that do not code for specific antigens, aiming to "wake up the immune system more rapidly" for universal application. A recent illustration of the universal vaccine approach came in a study led by Drs. Adam Grippin and Steven Lin of MD Anderson Cancer Center. They found that getting an mRNA-based Covid vaccine was linked to a significantly better response to cancer drugs for some patients, with Grippin suggesting mRNA acts as a "siren call to the overall immune system."
While federal funding remains tight, the most prominent mRNA cancer vaccines have attracted industry support and are not reliant on grants. Moderna expects to release data from its phase 3 melanoma trial this year. Dr. Vinod Balachandran emphasized the need for a "fast and potent, flexible and scalable" platform, stating that the RNA platform "at the moment seems to be superior."